NASDAQ: GLYCGlycomimetics Inc Stock Ownership - Who owns Glycomimetics?
Insider buying vs selling
Have Glycomimetics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Invus Public Equities LP | 10% Owner | 2024-08-08 | 260,873 | $0.19 | $50.09kSell |
| Invus Public Equities LP | 10% Owner | 2024-08-07 | 61,488 | $0.18 | $11.19kSell |
| Invus Public Equities LP | 10% Owner | 2024-08-06 | 55,732 | $0.18 | $10.20kSell |
| Invus Public Equities LP | 10% Owner | 2024-08-05 | 164,523 | $0.19 | $30.93kSell |
| Invus Public Equities LP | 10% Owner | 2024-08-02 | 286,200 | $0.20 | $57.24kSell |
| Invus Public Equities LP | 10% Owner | 2024-08-01 | 63,564 | $0.22 | $13.73kSell |
| Invus Public Equities LP | 10% Owner | 2024-07-30 | 756,835 | $0.22 | $167.26kSell |
| Invus Public Equities LP | 10% Owner | 2024-07-29 | 363,949 | $0.24 | $85.53kSell |
| Invus Public Equities LP | 10% Owner | 2024-07-26 | 258,335 | $0.24 | $62.52kSell |
| Edwin Rock | Chief Medical Officer | 2024-06-21 | 115,000 | $0.27 | $30.71kBuy |
GLYC insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when GLYC insiders and whales buy or sell their stock.
GLYC Shareholders
What type of owners hold Glycomimetics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Scott D. Sandell | 21.79% | 14,056,571 | $3.32M | Insider |
| M. James Barrett | 20.43% | 13,182,418 | $3.11M | Insider |
| Peter J. Barris | 20.43% | 13,182,418 | $3.11M | Insider |
| Bvf Inc | 14.79% | 9,544,262 | $2.25M | Institution |
| Siren LLC | 13.31% | 8,589,064 | $2.03M | Insider |
| Invus Public Equities LP | 9.79% | 6,317,565 | $1.49M | Insider |
| Logos Global Management LP | 8.37% | 5,400,000 | $1.27M | Institution |
| Adage Capital Partners GP LLC | 7.89% | 5,091,231 | $1.20M | Institution |
| New Enterprise Associates 10 L P | 7.74% | 4,995,664 | $1.18M | Insider |
| New Enterprise Associates 13 LP | 6.34% | 4,093,377 | $966.04k | Insider |
GLYC vs Biotech Stocks
Glycomimetics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.